» Articles » PMID: 37047709

Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 13
PMID 37047709
Authors
Affiliations
Soon will be listed here.
Abstract

Interferons (IFNs), divided into type I, type II, and type III IFNs represent proteins that are secreted from cells in response to various stimuli and provide important information for understanding the evolution, structure, and function of the immune system, as well as the signaling pathways of other cytokines and their receptors. They exert comparable, but also distinct physiologic and pathophysiologic activities accompanied by pleiotropic effects, such as the modulation of host responses against bacterial and viral infections, tumor surveillance, innate and adaptive immune responses. IFNs were the first cytokines used for the treatment of tumor patients including hairy leukemia, renal cell carcinoma, and melanoma. However, tumor cells often develop a transient or permanent resistance to IFNs, which has been linked to the escape of tumor cells and unresponsiveness to immunotherapies. In addition, loss-of-function mutations in IFN signaling components have been associated with susceptibility to infectious diseases, such as COVID-19 and mycobacterial infections. In this review, we summarize general features of the three IFN families and their function, the expression and activity of the different IFN signal transduction pathways, and their role in tumor immune evasion and pathogen clearance, with links to alterations in the major histocompatibility complex (MHC) class I and II antigen processing machinery (APM). In addition, we discuss insights regarding the clinical applications of IFNs alone or in combination with other therapeutic options including immunotherapies as well as strategies reversing the deficient IFN signaling. Therefore, this review provides an overview on the function and clinical relevance of the different IFN family members, with a specific focus on the MHC pathways in cancers and infections and their contribution to immune escape of tumors.

Citing Articles

In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo.

Kimura K, Aicher A, Niemeyer E, Areesawangkit P, Tilsed C, Fong K Vaccines (Basel). 2025; 13(2).

PMID: 40006725 PMC: 11861666. DOI: 10.3390/vaccines13020178.


Keratinocyte-Mediated Antigen Presentation in Psoriasis: Preliminary Insights from In Vitro Studies.

Zima K, Purzycka-Bohdan D, Szczerkowska-Dobosz A, Gabig-Ciminska M Int J Mol Sci. 2025; 25(24.

PMID: 39769151 PMC: 11676545. DOI: 10.3390/ijms252413387.


Variances in the Expression Profile of Circadian Clock-Related Genes in Astrocytic Brain Tumors.

Staszkiewicz R, Sobanski D, Pulka W, Gladysz D, Gadzielinski M, Strojny D Cancers (Basel). 2024; 16(13).

PMID: 39001398 PMC: 11240661. DOI: 10.3390/cancers16132335.


Combined analysis of single-cell sequencing and bulk transcriptome sequencing reveals new mechanisms for non-healing diabetic foot ulcers.

Chen R, Zou L PLoS One. 2024; 19(7):e0306248.

PMID: 38950058 PMC: 11216623. DOI: 10.1371/journal.pone.0306248.


AMPKα2 promotes tumor immune escape by inducing CD8+ T-cell exhaustion and CD4+ Treg cell formation in liver hepatocellular carcinoma.

Ouyang Y, Gu Y, Zhang X, Huang Y, Wei X, Tang F BMC Cancer. 2024; 24(1):276.

PMID: 38424484 PMC: 10905944. DOI: 10.1186/s12885-024-12025-y.

References
1.
Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A . Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell. 1989; 58(4):729-39. DOI: 10.1016/0092-8674(89)90107-4. View

2.
Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H . Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene. 2004; 23(55):8876-86. DOI: 10.1038/sj.onc.1208144. View

3.
van de Vosse E, van Dissel J . IFN-γR1 defects: Mutation update and description of the IFNGR1 variation database. Hum Mutat. 2017; 38(10):1286-1296. DOI: 10.1002/humu.23302. View

4.
Li Z, Metze D, Nashan D, Muller-Tidow C, Serve H, Poremba C . Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 2004; 123(4):737-45. DOI: 10.1111/j.0022-202X.2004.23408.x. View

5.
Osterlund P, Pietila T, Veckman V, Kotenko S, Julkunen I . IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol. 2007; 179(6):3434-42. DOI: 10.4049/jimmunol.179.6.3434. View